| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $792,665 ) |
| | 2025 | 2025 | PARMEDICS, INC | 41593 WINCHESTER RD | TEMECULA | CA | 92590-4857 | RIVERSIDE | USA | R44HL160424 | Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma | 000 | 3 | NIH | 3/25/2025 | $792,665 |
|
| Issue Date FY: 2024 ( Subtotal = $878,390 ) |
| | 2024 | 2024 | PARMEDICS, INC | 41593 WINCHESTER RD | TEMECULA | CA | 92590-4857 | RIVERSIDE | USA | R44HL160424 | Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma | 000 | 2 | NIH | 3/6/2024 | $878,390 |
| | 2024 | 2023 | PARMEDICS, INC | 41593 WINCHESTER RD | TEMECULA | CA | 92590-4857 | RIVERSIDE | USA | R41NS127637 | Protease-activated-receptor-2 antagonists for treatment of migraine pain | 000 | 1 | NIH | 5/28/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $610,351 ) |
| | 2023 | 2023 | PARMEDICS, INC. | 41593 WINCHESTER RD STE 228 | TEMECULA | CA | 92590-4860 | RIVERSIDE | USA | R41NS127637 | Protease-activated-receptor-2 antagonists for treatment of migraine pain | 000 | 1 | NIH | 1/13/2023 | $310,351 |
| | 2023 | 2023 | PARMEDICS, INC. | 41593 WINCHESTER RD STE 228 | TEMECULA | CA | 92590-4860 | RIVERSIDE | USA | R41NS127637 | Protease-activated-receptor-2 antagonists for treatment of migraine pain | 001 | 1 | NIH | 2/24/2023 | $310,351 |
| | 2023 | 2023 | PARMEDICS, INC. | 41593 WINCHESTER RD STE 228 | TEMECULA | CA | 92590-4860 | RIVERSIDE | USA | R41HL169048 | Development of small molecule Protease-activated-receptor-2 antagonists as oral asthma therapeutics | 000 | 1 | NIH | 9/14/2023 | $300,000 |
| | 2023 | 2023 | PARMEDICS, INC. | 41593 WINCHESTER RD STE 228 | TEMECULA | CA | 92590-4860 | RIVERSIDE | USA | R41NS127637 | Protease-activated-receptor-2 antagonists for treatment of migraine pain | 001 | 1 | NIH | 2/24/2023 | -$310,351 |
| | 2023 | 2021 | PARMEDICS, INC | 41593 WINCHESTER RD | TEMECULA | CA | 92590-4857 | RIVERSIDE | USA | R41HL160424 | Development of Small Molecule Antagonists of PAR-2 for treatment of asthma | 000 | 1 | NIH | 8/9/2023 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $283,387 ) |
| | 2021 | 2021 | PARMEDICS, INC. | 53 LA ESPIRAL | ORINDA | CA | 94563-1852 | CONTRA COSTA | USA | R41HL160424 | Development of Small Molecule Antagonists of PAR-2 for treatment of asthma | 000 | 1 | NIH | 9/1/2021 | $283,387 |
|
|
